STOCK TITAN
  1. Home
  2. Sec-filings
  3. NGNE
  4. [Form 4] Neurogene Inc. Insider Trading Activity

Neurogene (NGNE) CMO receives new stock option and RSU grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Neurogene Inc. reported that Chief Medical Officer Jordan Julie acquired equity awards on February 20, 2026. The awards include a stock option for 29,600 shares of common stock and 4,900 restricted stock units, both subject to multi‑year vesting tied to continued service.

Positive

  • None.

Negative

  • None.
Insider Jordan Julie
Role Chief Medical Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 29,600 $0.00 --
Grant/Award Common Stock 4,900 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 29,600 shares (Direct); Common Stock — 13,300 shares (Direct)
Footnotes (1)
  1. Consist of 4,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. Consist of (a) 8,400 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (b) 4,900 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. This option represents the right to purchase 29,600 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jordan Julie
(Last) (First) (Middle)
C/O NEUROGENE INC.
535 W 24TH STREET, 5TH FLOOR
(Street)
NEW YORK NY 10011
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Neurogene Inc. [ NGNE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/20/2026 A 4,900(1) A $0 13,300(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $17.64 02/20/2026 A 29,600 (3) 02/20/2036 Common Stock 29,600 $0 29,600 D
Explanation of Responses:
1. Consist of 4,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
2. Consist of (a) 8,400 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (b) 4,900 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
3. This option represents the right to purchase 29,600 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.
Remarks:
/s/ Donna M. Cochener, as attorney-in-fact for Julie Jordan 02/24/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Neurogene (NGNE) disclose about Jordan Julie’s recent Form 4 filing?

Neurogene reported that Chief Medical Officer Jordan Julie received new equity awards. On February 20, 2026, she was granted a 29,600-share stock option and 4,900 restricted stock units, both subject to time-based vesting and continued service conditions.

How many stock options did Neurogene’s CMO receive in the latest NGNE Form 4?

The CMO received a stock option covering 29,600 shares of Neurogene common stock. According to the disclosure, one quarter vests on the first anniversary of the grant date, with the remaining three quarters vesting in equal monthly installments through the fourth anniversary.

What restricted stock units were granted to Jordan Julie in Neurogene’s Form 4?

Jordan Julie was granted 4,900 restricted stock units on February 20, 2026. These RSUs will vest in three equal annual installments beginning on the first anniversary of the grant date, conditioned on her continued provision of services to Neurogene on each vesting date.

What is Jordan Julie’s Neurogene (NGNE) share ownership after the latest RSU grant?

After the 4,900-share restricted stock unit grant, Jordan Julie’s reported common stock holdings total 13,300 shares. This figure reflects direct ownership as reported in the filing and incorporates the newly awarded RSUs subject to future vesting.

How do Jordan Julie’s earlier RSU grants at Neurogene vest over time?

The filing notes 8,400 RSUs granted on March 26, 2025. These vest annually in equal installments on March 26, 2026, 2027 and 2028, with vesting dependent on her continued service to Neurogene on each scheduled vesting date.

What is the combined RSU vesting schedule for Neurogene CMO Jordan Julie?

The document describes 8,400 RSUs from March 26, 2025 vesting annually through 2028 and 4,900 RSUs from February 20, 2026 vesting annually through 2029, all conditioned on her continued service at each vesting point.